Discovery of a Daunorubicin Analogue That Exhibits Potent Antitumor Activity and Overcomes P-gp-Mediated Drug Resistance
- 6 January 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (3), 932-941
- https://doi.org/10.1021/jm050800q
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinolToxicology and Applied Pharmacology, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- P-glycoprotein: from genomics to mechanismOncogene, 2003
- RETRACTED: Structure of MsbA from Vibrio cholera: A Multidrug Resistance ABC Transporter Homolog in a Closed ConformationJournal of Molecular Biology, 2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Differential Chemosensitizing Effect of Two Glucosylceramide Synthase Inhibitors in Hepatoma CellsBiochemical and Biophysical Research Communications, 2001
- How Does the MRP/GS-X Pump Export Doxorubicin?JNCI Journal of the National Cancer Institute, 1995
- P‐glycoprotein‐mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cellsFEBS Letters, 1994
- Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistanceInternational Journal of Cancer, 1994
- Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approachPharmacology & Therapeutics, 1993